tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Morris RE et al. | Comparative immunopharmacologic effects of FK 506 and CyA in in vivo models of organ transplantation. | 1990 | Transplant. Proc. | pmid:1689885 |
| Li PK et al. | The complications of newer transplant antirejection drugs: treatment with cyclosporin A, OKT3, and FK506. | 1990 | Adverse Drug React Acute Poisoning Rev | pmid:1703724 |
| Todo S et al. | Early trials with FK 506 as primary treatment in liver transplantation. | 1990 | Transplant. Proc. | pmid:1689886 |
| McCauley J et al. | The effects of FK 506 on renal function after liver transplantation. | 1990 | Transplant. Proc. | pmid:1689887 |
| Kang Y et al. | Acute hemodynamic effects of FK 506 during and after orthotopic liver transplantation. | 1990 | Transplant. Proc. | pmid:1689889 |
| Jain AB et al. | FK 506 dosage in human organ transplantation. | 1990 | Transplant. Proc. | pmid:1689890 |
| Demetris AJ et al. | Pathologic observations in human allograft recipients treated with FK 506. | 1990 | Transplant. Proc. | pmid:1689891 |
| Shapiro R et al. | The side effects of FK 506 in humans. | 1990 | Transplant. Proc. | pmid:1689892 |
| Van Thiel DH et al. | Gastrointestinal and metabolic problems associated with immunosuppression with either CyA or FK 506 in liver transplantation. | 1990 | Transplant. Proc. | pmid:1689893 |
| Woo J et al. | The influence of FK-506 and low-concentration ciclosporin on human lymphocyte activation antigen expression and blastogenesis: a flow cytometric analysis. | 1990 | Scand. J. Immunol. | pmid:1690915 |
| Yasunami Y et al. | FK506 as the sole immunosuppressive agent for prolongation of islet allograft survival in the rat. | 1990 | Transplantation | pmid:1691535 |
| Metcalfe SM and Richards FM | Cyclosporine, FK506, and rapamycin. Some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. | 1990 | Transplantation | pmid:1691537 |
| Morimoto T et al. | Pancreaticoduodenal allotransplantation with FK 506 in the dog. | 1990 | Transplant. Proc. | pmid:1691550 |
| Yasunami Y et al. | Characterization of the immunosuppressive activity of FK 506 in rat islet allografts. | 1990 | Transplant. Proc. | pmid:1691557 |
| Thomson AW | FK-506 enters the clinic. | 1990 | Immunol. Today | pmid:1692221 |
| Saitoh Y et al. | Morphological rejection phases and cytotoxic activity in peripheral blood lymphocytes in canine lung allo-transplantation. | 1990 | Jpn J Surg | pmid:1692892 |
| Rosen MK et al. | Inhibition of FKBP rotamase activity by immunosuppressant FK506: twisted amide surrogate. | 1990 | Science | pmid:1693013 |
| Murase N et al. | Prevention of spontaneous diabetes in BB rats with FK 506. | 1990 | Lancet | pmid:1697397 |
| Justice RM et al. | The detection of proline isomerase activity in FK506-binding protein by two-dimensional 1H NMR exchange spectroscopy. | 1990 | Biochem. Biophys. Res. Commun. | pmid:1697463 |
| Todo S et al. | Liver, kidney, and thoracic organ transplantation under FK 506. | 1990 | Ann. Surg. | pmid:1697743 |
| Sakr MF et al. | FK 506 ameliorates the hepatic injury associated with ischemia. | 1990 | Life Sci. | pmid:1698241 |
| Kurasawa K et al. | The immunosuppressant FK-506 prevents progression of diabetes in nonobese diabetic mice. | 1990 | Clin. Immunol. Immunopathol. | pmid:1698584 |
| Miyagawa J et al. | Preventive effect of a new immunosuppressant FK-506 on insulitis and diabetes in non-obese diabetic mice. | 1990 | Diabetologia | pmid:1698679 |
| Lagodzinski Z et al. | Effect of FK506 and cyclosporine on primary and secondary skin allograft survival in mice. | 1990 | Immunology | pmid:1698713 |
| Woo J et al. | Influence of FK506 and cyclosporin A on alloantibody production and lymphocyte activation following blood transfusion. | 1990 | Clin. Exp. Immunol. | pmid:1702375 |
| Mattila PS et al. | The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes. | 1990 | EMBO J. | pmid:1702384 |
| Kawashima H et al. | Antigen-specific suppressor cells induced by FK506 in experimental autoimmune uveoretinitis in the rat. | 1990 | Invest. Ophthalmol. Vis. Sci. | pmid:1702408 |
| Wilkinson PC and Watson EA | FK506 and pertussis toxin distinguish growth-induced locomotor activation from attractant-stimulated locomotion in human blood lymphocytes. | 1990 | Immunology | pmid:1702750 |
| Metcalfe S and Milner J | Phosphatases PP1 and PP2A act after the G0/G1 interface in lymphocyte activation. | 1990 | Immunol. Lett. | pmid:1702753 |
| Takada K et al. | Determination of a novel potent immunosuppressant (FK-506) in rat serum and lymph by high-performance liquid chromatography with chemiluminescence detection. | 1990 | J. Chromatogr. | pmid:1703552 |
| Woo J et al. | Antigen presentation and HLA-DR expression by FK-506-treated human monocytes. | 1990 | Immunology | pmid:1703987 |
| Fung JJ et al. | Overview of FK506 in transplantation. | 1990 | Clin Transpl | pmid:1715740 |
| Pugh-Humphreys RG et al. | The influence of FK-506 on the thymus: an immunophenotypic and structural analysis. | 1990 | Immunology | pmid:1696242 |
| Collier SJ | Immunosuppressive drugs. | 1989-1990 | Curr. Opin. Immunol. | pmid:2484794 |
| McCauley J et al. | Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. | 1989 Dec 23-30 | Lancet | pmid:2481200 |
| Yoshimura N et al. | A new immunosuppressive agent, FK506, inhibits the expression of alloantigen-activated suppressor cells as well as the induction of alloreactivity. | 1989 | Transplant. Proc. | pmid:2468202 |
| Thomson AW et al. | Immunosuppressive activity, T-cell subset analysis, and acute toxicity of FK-506 in rats. | 1989 | Transplant. Proc. | pmid:2468203 |
| Sanghvi A et al. | Increased cyclosporine uptake by cells pretreated with FK506 and evidence for binding of both drugs to a common intracellular protein. | 1989 | Transplant. Proc. | pmid:2468204 |
| Takagishi K et al. | Effects of FK-506 on collagen arthritis in mice. | 1989 | Transplant. Proc. | pmid:2468205 |
| Arita C et al. | Effect of FK 506 (FR 900506) on collagen arthritis in rats: a preliminary report. | 1989 | Transplant. Proc. | pmid:2468206 |
| Morimoto T et al. | Blood levels of FK506 after intramuscular and intravenous administration in dogs. | 1989 | Transplant. Proc. | pmid:2468207 |
| Tsuchimoto S et al. | Orthotopic liver transplantation in rats receiving FK506. | 1989 | Transplant. Proc. | pmid:2468208 |
| Yokota K et al. | Comparative studies of FK506 and cyclosporine in canine orthotopic hepatic allograft survival. | 1989 | Transplant. Proc. | pmid:2468209 |
| Inagaki K et al. | Effects of FK506 and 15-deoxyspergualin in rat orthotopic liver transplantation. | 1989 | Transplant. Proc. | pmid:2468210 |
| Kay JE et al. | Inhibition of T-lymphocyte activation by the immunosuppressive drug FK-506. | 1989 | Immunology | pmid:2475433 |
| Moriyama S | [Experimental tracheal reconstruction by allotransplantation]. | 1989 | Nihon Kyobu Geka Gakkai Zasshi | pmid:2475555 |
| Freedman RB | Immunosuppression. Convergence of drug action. | 1989 | Nature | pmid:2477712 |
| Siekierka JJ et al. | A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. | 1989 | Nature | pmid:2477714 |
| Harding MW et al. | A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. | 1989 | Nature | pmid:2477715 |
| Kay JE et al. | The mechanism of action of the immunosuppressive drug FK-506. | 1989 | Cell. Immunol. | pmid:2478301 |